Phospholipid Screen IgG/IgM GENLISA™ ELISA

The acronym “aPL” (anti-phospholipid antibodies) indicates improperly antibodies directed against phospholipids negatively charged like Cardiolipin (CL), Phosphatidyl serine (PS) Phosphatidyl inositol (PI) and phosphatidic acid (PA); more correctly the term anti-phospholipid antibodies indicate those antibodies directed against the complex between ?2GPI and anionic phospholipids that can bind to the fifth domain of ?2GPI. Among these, the Cardiolipin is the most commonly used phospholipid as an antigen for determining the aPL with ELISA method. The antibodies directed against the complex between ?2GPI and negatively charged phospholipids, as Phosphatidyl serine (PS) Phosphatidyl inositol (PI) and phosphatidic acid (PA). Some researchers suggest the use of PS instead of Cardiolipin in ELISA assays, for a more precise diagnosis. However, these antibodies against phospholipids are less commonly used, even if their use may increase the clinical sensitivity of patients samples with suspected Anti-phospholipid Syndrome (APS), but it can? t replace the determination of autoantibodies anti-Cardiolipin.